Tetraphase Pharmaceuticals Inc. (TTPH) Upgraded at Zacks Investment Research
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm presently has a $4.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research’s price objective indicates a potential upside of 13.03% from the stock’s previous close.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Separately, Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Friday, August 5th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Tetraphase Pharmaceuticals has an average rating of “Hold” and an average price target of $9.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 3.46% during mid-day trading on Tuesday, hitting $3.63. The company had a trading volume of 140,213 shares. The firm has a 50-day moving average price of $3.82 and a 200-day moving average price of $4.27. Tetraphase Pharmaceuticals has a 52 week low of $3.12 and a 52 week high of $12.45. The firm’s market capitalization is $133.21 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.01. The company earned $1.20 million during the quarter, compared to analysts’ expectations of $2.05 million. Tetraphase Pharmaceuticals had a negative return on equity of 35.43% and a negative net margin of 821.25%. The company’s revenue for the quarter was down 63.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.72) earnings per share. Equities analysts forecast that Tetraphase Pharmaceuticals will post ($1.98) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of TTPH. Bellevue Group AG bought a new position in Tetraphase Pharmaceuticals during the first quarter valued at approximately $102,000. Teton Advisors Inc. bought a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $103,000. Parametric Portfolio Associates LLC bought a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $128,000. ProShare Advisors LLC increased its position in Tetraphase Pharmaceuticals by 1.2% in the second quarter. ProShare Advisors LLC now owns 31,696 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 383 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in Tetraphase Pharmaceuticals by 2,618.8% in the second quarter. Nisa Investment Advisors LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 41,900 shares during the period. 59.41% of the stock is owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.